在胰腺癌中,KLF5通过AAA+ ATPase协活性剂RUVBL1和RUVBL2实现了二分化血统程序
Patrick J Cunniff1,2, Nicole Sivetz1,2, Damianos Skopelitis1
1Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA.
Nature communications
|November 15, 2025
概括
克鲁佩尔样因子5 (KLF5) 动态调节胰腺癌细胞的身份. AAA+ ATPases RUVBL1/2是必不可少的联合激活剂,它们的抑制为胰腺管道腺癌 (PDAC) 提供了潜在的治疗策略.
科学领域:
- 分子生物学分子生物学
- 癌症研究 癌症研究
- 细胞的可塑性 细胞的可塑性
背景情况:
- 血统可塑性驱动胰腺管腺癌 (PDAC) 异质性和治疗耐药性.
- 了解PDAC细胞身份的调节者对于开发有效疗法至关重要.
研究的目的:
- 在PDAC中识别表皮层血统身份的关键调节者.
- 研究AAA+ ATPases RUVBL1/2在KLF5介导的转录调节中的作用.
- 探索RUVBL1/2抑制剂作为PDAC的治疗策略.
主要方法:
- 无偏见的蛋白质和遗传查以识别KLF5联合激活剂.
- 生物化学试验研究KLF5-RUVBL1/2相互作用和ATP水解.
- 使用RUVBL1/2 ATPase活性小分子抑制剂的体内研究.
主要成果:
- KLF5充当PDAC中古典和基底类转录程序的主调节者.
- RUVBL1和RUVBL2被确定为KLF5.5的重要协活性剂.
- 通过RUVBL1/2进行ATP水解对于KLF5向谱系特定增强剂的招募至关重要.
- 针对RUVBL1/2 ATPase活性的小分子抑制剂通过抑制KLF5-依赖转录,体内表现出抗PDAC作用.
结论:
- 描述了涉及KLF5和RUVBL1/2的依赖ATP水解的转录协活性的一种新机制.
- 准RUVBL1/2 ATPase活性代表了调节癌中异常血统程序的有希望的治疗途径.
更多相关视频
07:08Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
1.3K
10:13A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
Published on: July 3, 2013
11.6K
相关概念视频
02:37Restarting Stalled Replication Forks
6.2K
DNA replication is initiated at sites containing predefined DNA sequences known as origins of replication. DNA is unwound at these sites by the minichromosome maintenance (MCM) helicase and other factors such as Cdc45 and the associated GINS complex.The unwound single strands are protected by replication protein A (RPA) until DNA polymerase starts synthesizing DNA at the 5’ end of the strand in the same direction as the replication fork. To prevent the replication fork from falling apart,...
6.2K
00:50Anaphase Promoting Complex
3.3K
The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
3.3K
02:53Adaptive Mechanisms in Cancer Cells
6.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.9K
01:22PI3K/mTOR/AKT Signaling Pathway
5.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.3K
01:35Cancer Cell Migration through Invadopodia
3.2K
Invadosome is a broad category of cell surface structures with proteolytic activity that degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
3.2K